Cover Image
市場調查報告書

生技仿製藥的全球市場 - 至2021年的預測:各產品 (重組非糖化蛋白質 (胰島素、rHGH、干擾素)、糖化 (mAb、EPO) 肽 (升糖素、抑鈣素)、各製造 (公司內部、CMO)、各用途 (腫瘤、血液疾病)

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO), Application (Oncology, Blood Disorders) - Global Forecast to 2021

出版商 MarketsandMarkets 商品編碼 290171
出版日期 內容資訊 英文 154 Pages
訂單完成後即時交付
價格
Back to Top
生技仿製藥的全球市場 - 至2021年的預測:各產品 (重組非糖化蛋白質 (胰島素、rHGH、干擾素)、糖化 (mAb、EPO) 肽 (升糖素、抑鈣素)、各製造 (公司內部、CMO)、各用途 (腫瘤、血液疾病) Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO), Application (Oncology, Blood Disorders) - Global Forecast to 2021
出版日期: 2017年01月05日 內容資訊: 英文 154 Pages
簡介

全球生技仿製藥市場預計2016∼2021年以26.3%的年複合成長率擴大,預計從2016年的33億9,000萬美元到2021年達到109億美元。

本報告提供全球生技仿製藥市場相關調查,市場趨勢,各產品、各製造、各用途、各地區的趨勢,及打入市場的主要企業簡介等彙整資料。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 高級見解

第5章 市場概要

  • 簡介
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會
    • 課題
  • 主要的開發中產品
  • 法律規章預測
  • 生技仿製藥服務業趨勢
    • 簡介
    • CMO
    • CRO
    • 其他

第6章 各產品類型市場

  • 簡介
  • 重組的非糖化蛋白質
    • 胰島素
    • 重組的人體生長荷爾蒙 (rHGH)
    • 顆粒細胞增生因子
    • 干擾素
  • 重組的糖化蛋白質
    • 促血紅細胞生長素
    • 單株抗體
    • 促濾泡素
  • 重組的肽
    • 升糖素
    • 抑鈣素

第7章 各製造類型市場

  • 簡介
  • 公司內部製造
  • CMO

第8章 各用途市場

  • 簡介
  • 腫瘤
  • 慢性及自體免疫疾病
  • 血液疾病
  • 生長激素缺乏
  • 感染疾病
  • 其他

第9章 各地區市場

  • 簡介
  • 北美
  • 歐洲
  • 亞洲
  • 其他

第10章 競爭環境

  • 概要
  • 市場佔有率分析
  • 競爭趨勢
    • 法律規章認證
    • 協定、聯合、聯盟
    • 產品上市
    • 收購
    • 擴充
    • 其他

第11章 企業簡介

  • 簡介
  • PFIZER INC.
  • SANDOZ INTERNATIONAL GMBH (A DIVISION OF NOVARTIS INTERNATIONAL AG)
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • F. HOFFMANN-LA ROCHE LTD.
  • AMGEN INC.
  • BIOCON LTD.
  • DR. REDDY'S LABORATORIES
  • CELLTRION INC.
  • MYLAN INC.
  • SAMSUNG BIOEPIS

第12章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BT 2160

Title: Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application (Oncology, Blood Disorders) - Global Forecast To 2021.

The global biosimilars market is expected to reach USD 10.90 billion by 2021 from USD 3.39 billion in 2016, at a CAGR of 26.3%. The biosimilars market is broadly classified into product, manufacturing type, application, and region.

On the basis of product, the biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins segment is estimated to account for the largest share of the biosimilars market, in 2016. Factors such as new product launches, cost-effectiveness, growing incidence of diabetes, and presence of many biosimilar versions of insulin in the pipeline are driving growth in this market.

On the basis of manufacturing type, the market is segmented into in-house manufacturing and contract manufacturing organizations. The contract manufacturing organizations segment is projected to witness the highest CAGR during the forecast period.

On the basis of application, the market is segmented into oncology, blood disorders, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. In 2016, the oncology segment is expected to account for the largest share of the market.

Geographically, the biosimilars market is dominated by Europe, followed by Asia, North America, and the Rest of the World (RoW). Growth in the European market is attributed to the growing pressure to curtail healthcare costs, patent expiry of biologics & the arrival of new biosimilars, and the rising incidence of chronic disorders.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.

The key players in the biosimilars market include Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Biocon Ltd. (India), Dr. Reddy's Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion Inc. (South Korea), and Samsung Bioepis (South Korea).

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the biosimilars market. The report analyses the biosimilars market by product, manufacturing type, and application.
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the biosimilars market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various biosimilars products across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKET COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. SECONDARY DATA
    • 2.1.1. KEY DATA FROM SECONDARY SOURCES
  • 2.2. PRIMARY DATA
    • 2.2.1. KEY DATA FROM PRIMARY SOURCES
  • 2.3. MARKET SIZE ESTIMATION
    • 2.3.1. BOTTOM-UP APPROACH
    • 2.3.2. TOP-DOWN APPROACH
  • 2.4. MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. BIOSIMILARS: MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: BIOSIMILARS MARKET, BY PRODUCT
  • 4.3. BIOSIMILARS MARKET SIZE, BY APPLICATION, 2016 VS. 2021

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Rising incidences of diseases
      • 5.2.1.2. Increasing demand for biosimilar drugs due to their cost-effectiveness
      • 5.2.1.3. Growing pressure to curtail healthcare expenditure
      • 5.2.1.4. Rising geriatric population
      • 5.2.1.5. Strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars
      • 5.2.1.6. Increasing government support and initiatives to develop and promote biosimilars
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Complexities in manufacturing and high costs
      • 5.2.2.2. Innovative strategies by biologic drug manufacturers
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Emerging markets
      • 5.2.3.2. New indications and patent expiry of biologic products
    • 5.2.4. CHALLENGE
      • 5.2.4.1. Stringent regulatory requirements to adversely affect investments in biosimilars
  • 5.3. KEY PIPELINE PRODUCTS
  • 5.4. REGULATORY OUTLOOK
    • 5.4.1. NORTH AMERICA
      • 5.4.1.1. U.S.
      • 5.4.1.2. Canada
    • 5.4.2. EUROPE
    • 5.4.3. ASIA
      • 5.4.3.1. China
      • 5.4.3.2. India
      • 5.4.3.3. Japan
      • 5.4.3.4. South Korea
    • 5.4.4. REST OF THE WORLD
      • 5.4.4.1. Brazil
      • 5.4.4.2. Mexico
      • 5.4.4.3. Argentina
      • 5.4.4.4. Saudi Arabia
  • 5.5. BIOSIMILARS SERVICES INDUSTRY INSIGHTS
    • 5.5.1. INTRODUCTION
    • 5.5.2. CONTRACT MANUFACTURING ORGANIZATIONS
    • 5.5.3. CONTRACT RESEARCH ORGANIZATIONS
    • 5.5.4. OTHER SERVICES (NONCLINICAL & BIOINFORMATICS)

6. BIOSIMILARS MARKET, BY TYPE OF PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. RECOMBINANT NON-GLYCOSYLATED PROTEINS
    • 6.2.1. INSULIN
    • 6.2.2. RECOMBINANT HUMAN GROWTH HORMONE (RHGH)
    • 6.2.3. GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM)
    • 6.2.4. INTERFERONS
  • 6.3. RECOMBINANT GLYCOSYLATED PROTEINS
    • 6.3.1. ERYTHROPOIETIN (EPO)
    • 6.3.2. MONOCLONAL ANTIBODIES (MABS)
    • 6.3.3. FOLLITROPIN
  • 6.4. RECOMBINANT PEPTIDES
    • 6.4.1. GLUCAGON
    • 6.4.2. CALCITONIN

7. BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING

  • 7.1. INTRODUCTION
  • 7.2. IN-HOUSE MANUFACTURING
  • 7.3. CONTRACT MANUFACTURING ORGANIZATIONS

8. BIOSIMILARS MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. ONCOLOGY
  • 8.3. CHRONIC AND AUTOIMMUNE DISEASES
  • 8.4. BLOOD DISORDERS
  • 8.5. GROWTH HORMONE DEFICIENCY
  • 8.6. INFECTIOUS DISEASES
  • 8.7. OTHER APPLICATIONS

9. BIOSIMILARS MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. U.S.
    • 9.2.2. CANADA
  • 9.3. EUROPE
    • 9.3.1. GERMANY
    • 9.3.2. FRANCE
    • 9.3.3. U.K.
    • 9.3.4. ITALY
    • 9.3.5. SPAIN
    • 9.3.6. REST OF EUROPE
  • 9.4. ASIA
    • 9.4.1. CHINA
    • 9.4.2. INDIA
    • 9.4.3. JAPAN
    • 9.4.4. SOUTH KOREA
    • 9.4.5. REST OF ASIA (ROA)
  • 9.5. REST OF THE WORLD (ROW)

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS
  • 10.3. COMPETITIVE SITUATION AND TRENDS
    • 10.3.1. REGULATORY APPROVALS
    • 10.3.2. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • 10.3.3. PRODUCT LAUNCHES
    • 10.3.4. ACQUISITIONS
    • 10.3.5. EXPANSIONS
    • 10.3.6. OTHER DEVELOPMENTS

11. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 11.1. INTRODUCTION
  • 11.2. PFIZER INC.
  • 11.3. SANDOZ INTERNATIONAL GMBH (A DIVISION OF NOVARTIS INTERNATIONAL AG)
  • 11.4. TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 11.5. F. HOFFMANN-LA ROCHE LTD.
  • 11.6. AMGEN INC.
  • 11.7. BIOCON LTD.
  • 11.8. DR. REDDY'S LABORATORIES
  • 11.9. CELLTRION INC.
  • 11.10. MYLAN INC.
  • 11.11. SAMSUNG BIOEPIS

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. INSIGHTS OF INDUSTRY EXPERTS
  • 12.2. DISCUSSION GUIDE
  • 12.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.5. AVAILABLE CUSTOMIZATIONS
  • 12.6. RELATED REPORTS
  • 12.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: BIOSIMILARS MARKET SUMMARY
  • TABLE 2: BIOSIMILARS MARKET: MAJOR COLLABORATIONS (2012-2015)
  • TABLE 3: LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
  • TABLE 4: BIOSIMILARS IN CLINICAL TRIALS
  • TABLE 5: STATUS OF REGULATORY PATHWAY IN NORTH AMERICA
  • TABLE 6: SUBSTITUTION STATUS IN EUROPEAN COUNTRIES
  • TABLE 7: STATUS OF REGULATORY PATHWAY IN ASIA
  • TABLE 8: STATUS OF REGULATORY PATHWAY IN THE ROW
  • TABLE 9: JOINT VENTURES BETWEEN CMOS & PHARMACEUTICAL COMPANIES FOR BIOSIMILARS
  • TABLE 10: BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • TABLE 11: BIOSIMILAR RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 12: BIOSIMILAR RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: NORTH AMERICA: BIOSIMILAR RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 14: EUROPE: BIOSIMILAR RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 15: ASIA: BIOSIMILAR RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 16: BIOSIMILAR INSULIN MARKET SIZE, BY REGION, 2014 -2021 (USD MILLION)
  • TABLE 17: BIOSIMILAR RECOMBINANT HUMAN GROWTH HORMONE MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY-STIMULATING FACTOR PRODUCTS FROM 2013 TO 2016
  • TABLE 19: BIOSIMILAR GRANULOCYTE COLONY-STIMULATING FACTOR MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: BIOSIMILAR INTERFERONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 21: BIOSIMILAR RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 22: BIOSIMILAR RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: NORTH AMERICA: BIOSIMILAR RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 24: EUROPE: BIOSIMILAR RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 25: ASIA: BIOSIMILAR RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 26: BIOSIMILAR ERYTHROPOIETIN MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 27: BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 28: BIOSIMILAR FOLLITROPIN MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 29: BIOSIMILAR RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 30: BIOSIMILAR RECOMBINANT PEPTIDES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 31: NORTH AMERICA: BIOSIMILAR RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 32: EUROPE: BIOSIMILAR RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 33: ASIA: BIOSIMILAR RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 34: BIOSIMILAR GLUCAGON MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 35: BIOSIMILAR CALCITONIN MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 36: BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2014-2021 (USD MILLION)
  • TABLE 37: BIOSIMILARS MARKET SIZE FOR IN-HOUSE MANUFACTUIRNG, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 38: BIOSIMILARS MARKET SIZE FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 39: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 40: BIOSIMILARS MARKET SIZE FOR ONCOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 41: BIOSIMILARS MARKET SIZE FOR CHRONIC AND AUTOIMMUNE DISEASES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 42: BIOSIMILARS MARKET SIZE FOR BLOOD DISORDERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 43: BIOSIMILARS MARKET SIZE FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 44: BIOSIMILARS MARKET SIZE FOR INFECTIOUS DISEASES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 45: BIOSIMILARS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 46: BIOSIMILARS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 47: NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 48: NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 49: NORTH AMERICA: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 50: NORTH AMERICA: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 51: NORTH AMERICA: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 52: NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 53: NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2014-2021 (USD MILLION)
  • TABLE 54: U.S.: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 55: CANADA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 56: EUROPE: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 57: EUROPE: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 58: EUROPE: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 59: EUROPE: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 60: EUROPE: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 61: EUROPE: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 62: EUROPE: BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2014-2021 (USD MILLION)
  • TABLE 63: GERMANY: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 64: FRANCE: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 65: U.K.: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 66: ITALY: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 67: SPAIN: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 68: ROE: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 69: ASIA: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 70: ASIA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 71: ASIA: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 72: ASIA: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 73: ASIA: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 74: ASIA: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 75: ASIA: BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2014-2021 (USD MILLION)
  • TABLE 76: CHINA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 77: INDIA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 78: JAPAN: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 79: SOUTH KOREA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 80: ROA: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 81: ROW: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 82: ROW: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 83: ROW: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 84: ROW: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 85: ROW: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 86: REGULATORY APPROVALS, 2013-2016
  • TABLE 87: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2013-2016
  • TABLE 88: PRODUCT LAUNCHES, 2013-2016
  • TABLE 89: ACQUISITIONS, 2013-2016
  • TABLE 90: EXPANSIONS, 2013-2016
  • TABLE 91: OTHER DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 1: RESEARCH METHODOLOGY
  • FIGURE 2: BIOSIMILARS MARKET: BOTTOM-UP APPROACH
  • FIGURE 3: TOP-DOWN APPROACH
  • FIGURE 4: DATA TRIANGULATION METHODOLOGY
  • FIGURE 5: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD BILLION)
  • FIGURE 6: BIOSIMILARS MARKET SIZE, BY TYPE OF MANUFACTURING, 2016 VS. 2021 (USD BILLION)
  • FIGURE 7: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD BILLION)
  • FIGURE 8: GEOGRAPHICAL SNAPSHOT OF THE BIOSIMILARS MARKET
  • FIGURE 9: BIOSIMILARS MARKET TO REGISTER A HIGH, DOUBLE-DIGIT GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 10: RECOMBINANT NON-GLYCOSYLATED PROTEINS SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 11: ONCOLOGY SEGMENT WILL CONTINUE TO DOMINATE THE BIOSIMILARS MARKET IN 2021
  • FIGURE 12: ASIA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 13: BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 14: GLOBAL INCIDENCES OF TOP TEN CANCER
  • FIGURE 15: GLOBAL INCIDENCES OF DIABETIES
  • FIGURE 16: BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2014-2021
  • FIGURE 17: IN-HOUSE MANUFACTURING SEGMENT TO DOMINATE THE BIOSIMILARS MARKET IN 2016
  • FIGURE 18: ONCOLOGY TO DOMINATE THE BIOSIMILARS MARKET IN 2016
  • FIGURE 19: GLOBAL CANCER INCIDENCE, BY REGION, 2012-2020
  • FIGURE 20: EUROPE TO DOMINATE THE BIOSIMILARS MARKET IN 2016
  • FIGURE 21: NORTH AMERICA: BIOSIMILARS MARKET SNAPSHOT
  • FIGURE 22: GLUCAGON SEGMENT TO HOLD THE LARGEST SHARE OF THE NORTH AMERICAN MARKET
  • FIGURE 23: EUROPE: BIOSIMILARS MARKET SNAPSHOT
  • FIGURE 24: ERYTHROPOIETIN SEGMENT TO HOLD THE LARGEST SHARE OF THE EUROPEAN MARKET
  • FIGURE 25: ASIA: BIOSIMILARS MARKET SNAPSHOT
  • FIGURE 26: RECOMBINANT NON-GLYCOSYLATED PROTEINS SEGMENT TO HOLD LARGEST SHARE OF THE ASIAN MARKET
  • FIGURE 27: ONCOLOGY SEGMENT TO HOLD LARGEST SHARE IN THE ASIAN MARKET IN 2016
  • FIGURE 28: ROW: BIOSIMILARS MARKET SNAPSHOT
  • FIGURE 29: GRANULOCYTE COLONY-STIMULATING FACTOR SEGMENT TO HOLD LARGEST SHARE OF THE ROW MARKET IN 2016
  • FIGURE 30: KEY DEVELOPMENTS ADOPTED BY MARKET PLAYERS BETWEEN 2013 AND 2016
  • FIGURE 31: GLOBAL BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2015
  • FIGURE 32: BATTLE FOR MARKET SHARE: REGULATORY APPROVALS WAS THE KEY STRATEGY PURSUED BY MARKET PLAYERS BETWEEN 2013 & 2016
  • FIGURE 33: PRODUCT BENCHMARKING FOR THE TOP 3 PLAYERS
  • FIGURE 34: COMPANY SNAPSHOT: PFIZER INC.
  • FIGURE 35: COMPANY SNAPSHOT: SANDOZ INTERNATIONAL GMBH
  • FIGURE 36: COMPANY SNAPSHOT: TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • FIGURE 37: COMPANY SNAPSHOT: F. HOFFMANN-LA ROCHE LTD.
  • FIGURE 38: COMPANY SNAPSHOT: AMGEN INC.
  • FIGURE 39: COMPANY SNAPSHOT: BIOCON LTD.
  • FIGURE 40: COMPANY SNAPSHOT: DR. REDDY'S LABORATORIES
  • FIGURE 41: COMPANY SNAPSHOT: CELLTRION INC.
  • FIGURE 42: COMPANY SNAPSHOT: MYLAN INC.
Back to Top